Clinical management and outcome of eclampsia at Rajavithi Hospital.
The purpose of this clinical study was to review experience in the management, and outcome of eclamptic patients at Rajavithi Hospital. Standardized treatment for all cases of eclampsia has consisted of magnesium sulfate intravenously and intramuscularly to control convulsions by means of Chesley and Tepper's regimen, intravenous hydralazine intermittently to lower diastolic blood pressure when it exceeds 110 mmHg, and initiation of delivery as soon as the patient has regained consciousness and is stable. During a ten-year period there were 167,200 deliveries and 90 eclamptic patients, yielding an incidence of eclampsia of 1 in 1,857 deliveries. There were three maternal deaths (3.3%) due to intracerebral hemorrhage. Serious adverse maternal outcomes were more frequent in women whose convulsions occurred before delivery. Excluding postpartum cases, perinatal mortality of fetuses weighing 1,000 g or more was 11.7 per cent. Magnesium sulfate is the drug of choice for treatment of eclamptic convulsions. In most situations, clinical assessment of deep tendon reflexes, respirations, and urine output is adequate to monitor maternal magnesium toxicity without the need to determine actual maternal serum magnesium levels.
Chinayon
P
P
Department of Obstetrics and Gynecology, Rajavithi Hospital, Bangkok, Thailand.
D002543:Cerebral Hemorrhage / Q000209:etiology / Q000401:mortality; D004461:Eclampsia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D008274:Magnesium / Q000097:blood; D008278:Magnesium Sulfate / Q000627:therapeutic use; D008428:Maternal Mortality; D011247:Pregnancy; D012640:Seizures / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D013785:Thailand / Q000453:epidemiology
D008278:Magnesium Sulfate; D008274:Magnesium